$8.35
2.33% yesterday
Nasdaq, Sep 24, 10:00 pm CET
ISIN
US03152W1099
Symbol
FOLD

Amicus Therapeutics, Inc. Stock price

$8.35
+0.87 11.63% 1M
-0.34 3.91% 6M
-1.07 11.36% YTD
-2.87 25.58% 1Y
-1.68 16.75% 3Y
-5.45 39.49% 5Y
-7.02 45.67% 10Y
-6.08 42.13% 20Y
Nasdaq, Closing price Wed, Sep 24 2025
+0.19 2.33%
ISIN
US03152W1099
Symbol
FOLD
Industry

Key metrics

Basic
Market capitalization
$2.6b
Enterprise Value
$2.7b
Net debt
$160.3m
Cash
$231.0m
Shares outstanding
308.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.5 | 4.0
EV/Sales
4.8 | 4.3
EV/FCF
negative
P/B
12.6
Financial Health
Equity Ratio
24.7%
Return on Equity
-28.9%
ROCE
3.9%
ROIC
-
Debt/Equity
1.9
Financials (TTM | estimate)
Revenue
$571.2m | $639.1m
EBITDA
$33.0m | $88.8m
EBIT
$25.0m | $57.8m
Net Income
$-38.1m | $-15.4m
Free Cash Flow
$-48.9m
Growth (TTM | estimate)
Revenue
25.4% | 21.0%
EBITDA
276.4% | 108.3%
EBIT
191.4% | 69.6%
Net Income
68.1% | 72.6%
Free Cash Flow
-1.7%
Margin (TTM | estimate)
Gross
90.4%
EBITDA
5.8% | 13.9%
EBIT
4.4%
Net
-6.7% | -2.4%
Free Cash Flow
-8.6%
More
EPS
$-0.1
FCF per Share
$-0.2
Short interest
7.1%
Employees
499
Rev per Employee
$1.1m
Show more

Is Amicus Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Amicus Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Amicus Therapeutics, Inc. forecast:

15x Buy
83%
3x Hold
17%

Analyst Opinions

18 Analysts have issued a Amicus Therapeutics, Inc. forecast:

Buy
83%
Hold
17%

Financial data from Amicus Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
571 571
25% 25%
100%
- Direct Costs 55 55
20% 20%
10%
516 516
26% 26%
90%
- Selling and Administrative Expenses 338 338
14% 14%
59%
- Research and Development Expense 145 145
13% 13%
25%
33 33
276% 276%
6%
- Depreciation and Amortization 7.90 7.90
9% 9%
1%
EBIT (Operating Income) EBIT 25 25
191% 191%
4%
Net Profit -38 -38
68% 68%
-7%

In millions USD.

Don't miss a Thing! We will send you all news about Amicus Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amicus Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
16 days ago
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 3:20 PM EDT Company Participants Sebastien Martel - Chief Business Officer Jeffrey Castelli - Chief Development Officer Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst Okay. Great. I'm Max Skor, a biotech analys...
Neutral
GlobeNewsWire
17 days ago
Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda®
Neutral
GlobeNewsWire
26 days ago
V.O.S. Selections, Inc.; Plastic Services and Products, LCC, d/b/a Genova Pipe; MicroKits, LCC; FishUSA Inc.; Terry Precision Cycling LLC v. President Donald J. Trump, et al. V.O.S. Selections, Inc.; Plastic Services and Products, LCC, d/b/a Genova Pipe; MicroKits, LCC; FishUSA Inc.; Terry Precision Cycling LLC v. President Donald J. Trump, et al.
More Amicus Therapeutics, Inc. News

Company Profile

Amicus Therapeutics, Inc. is a biotechnology company. It engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product includes migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Head office United States
CEO Bradley Campbell
Employees 499
Founded 2002
Website www.amicusrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today